Prostate cancer‐specific death5
It is very uncertain whether whole gland primary cryotherapy changes time to death from prostate cancer (absolute effects:… compared with external beam radiotherapy (EBRT) (very low certainty).
1 finding from 1 review
Quality of life ‐ urinary function
1 finding from 1 review
Quality of life ‐ bowel function
1 finding from 1 review
Quality of life ‐ sexual function
1 finding from 1 review
Major adverse events
It is very uncertain whether whole gland primary cryotherapy changes major adverse events compared with external beam radiotherapy (EBRT) (very low certainty).
1 finding from 1 review
Time to death from any cause (absolute effects: overall mortality)
It is very uncertain whether whole gland primary cryotherapy changes time to death from any cause (absolute effects: overall mortality) compared with external beam radiotherapy (EBRT) (very low certainty).
1 finding from 1 review
Secondary interventions for treatment failure ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants requiring dose reduction · early triple‐negative breast cancer
Platinum‐containing chemotherapy probably leads to higher participants requiring dose reduction compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Anaemia (grade ≥ 3) · early triple‐negative breast cancer
Platinum‐containing chemotherapy probably leads to higher anaemia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Febrile neutropenia (grade III/IV) · early triple‐negative breast cancer
Platinum‐containing chemotherapy showed no clear difference in febrile neutropenia (grade III/IV) compared with chemotherapy without platinum (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · early triple‐negative breast cancer
1 finding from 1 review
Quality of life · early triple‐negative breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression to visual loss (loss of 3 or more lines on logMAR chart) · people with neovascular AMD
Radiotherapy showed no clear difference in loss of 3 or more lines of best‐corrected visual acuity Measured… compared with control (low certainty).
1 finding from 1 review
RR 0.82 [0.64, 1.04]
Studies not reported
Low
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Contrast sensitivity (log contrast threshold) Measured using a Pelli‐Robson chart. Higher scores represent better contrast sensitivity. · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
New vessel growth Measured using fluorescein angiography or fundus photographs · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Quality of life · people with neovascular AMD
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Any adverse outcome · people with neovascular AMD
Radiotherapy may leads to lower any adverse outcome compared with control (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Number of anti‐VEGF injections · people with neovascular AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · advanced gastric and oesophago‐gastric junction adenocarcinoma
Chemotherapy probably leads to lower overall survival compared with placebo, best supportive care (BSC) or no treatment (moderate certainty).
1 finding from 1 review